Contract award · SPE2DS22F0021
8508632018!BINAXNOW COVID-19 ANTIGEN SEL
Awarded to ABBOTT RAPID DX NORTH AMERICA, LLC · CAGE 5C4F2
Latest reported total obligated
$85.3M
Net observed obligations
$85.3M
Observed contract actions
30
Observed period
FY2022–FY2024
Reported totals are cumulative values from the latest available award record. Observed obligations and actions reflect Mimir's FY2019 onward transaction window and may omit earlier activity.
Award parties and scope
ContractorABBOTT RAPID DX NORTH AMERICA, LLC
CAGE5C4F2
Recipient UEIP782RNU1NNK3
Ultimate parentABBOTT RAPID DX NORTH AMERICA LLC
Parent UEIL3AXXYLB3V56
CustomerDefense Logistics Agency
Performance locationORLANDO, FLORIDA, UNITED STATES
Procurement details
Reported performance startOct 20, 2021
First observed actionOct 20, 2021
Latest observed actionFeb 13, 2024
Reported current value$85.3M
Reported potential value$85.3M
PSC6640
NAICS325412 · Pharmaceutical Preparation Manufacturing
CompetitionFULL AND OPEN COMPETITION AFTER EXCLUSION OF SOURCES
PricingFIRM FIXED PRICE
Annual observed obligations
FY2022
$86.9M
FY2023
-$1.6M
FY2024
-$51.6K
Continue exploring
Ask Mimir about SPE2DS22F0021
Continue with this contract award already in context.
ContinueExplore the full award in Mimir
Open the complete action history and connected analysis in the platform.